---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Co-prescribed/Concomitant therapies. Topics: Add-on to standard of care in the phase 3 trial, Background antihypoglycemic therapies weaned during expanded access, Tumor-directed therapies given with ersodetug, and Reduction of background therapy and monotherapy: congenital hyperinsulinism extension. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Add-on to standard of care in the phase 3 trial

> “The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).”
> “Every study participant will receive ersodetug doses weekly for 8 weeks alongside their usual treatments for hypoglycemia at a dose of 9 mg/kg.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-2.1.2.12-2"></a>

### Background antihypoglycemic therapies weaned during expanded access

> “All patients received ersodetug in open-label fashion at doses of 6 or 9 mg/ kg every 1-2 weeks initially, followed by a frequency of every 2-4 weeks as tolerated, as add on to standard of care (e.g. diazoxide, somatostatin analogues, etc.), which could be weaned as appropriate”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

> “All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “In several cases, other background medical therapies to prevent hypoglycemia were able to be weaned or stopped, and patients were able to resume tumor-directed therapies for treatment of their underlying cancer.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.12-3"></a>

### Tumor-directed therapies given with ersodetug

> “Within 8 weeks of ersodetug initiation, nearly all individuals (n = 7) were able to proceed with tumor-directed therapies, including chemotherapy (n = 7), surgery (n = 4), and other medical procedures such as hepatic arterial embolization (n = 5).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.12-4"></a>

### Reduction of background therapy and monotherapy: congenital hyperinsulinism extension

> “These glycemic benefits have enabled a concurrent significant overall reduction in background SOC therapies (e.g., diazoxide, somatostatin analogs, and/or regular tube feeds), with a significant number of patients now receiving ersodetug as monotherapy, which we believe is a potential indicator of ersodetug’s underlying efficacy.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
